---
schema_version: "secwatch.filing_event.v1"
accession: "0001232524-25-000025"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:04:01.969059+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jazz Q1 revenues flat at $898M; GAAP net loss widens to $92.5M; updated guidance after Chimerix

## Summary
- GAAP net loss $92.5M ($1.52 loss/share) vs $14.6M loss in 1Q24; adjusted net income $105.2M ($1.68 EPS) vs $178.4M ($2.63).
- Xywav revenue $344.8M (+9% YoY), Epidiolex $217.7M (+10% YoY); Xyrem fell 42% to $37.2M.
- Affirmed 2025 total revenue guidance $4.15-4.40B; updated to reflect Chimerix acquisition and Xyrem settlements.
- Completed Chimerix acquisition in April; added dordaviprone; PDUFA Aug 18, 2025 for recurrent H3 K27M-mutant glioma.
- Submitted sNDA for Zepzelca in 1L ES-SCLC maintenance; positive CHMP opinion for zanidatamab in 2L BTC.

## SEC filing metadata
- accession: 0001232524-25-000025
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/0001232524-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000123252425000025/jazz-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001232524-25-000025
- JSON: https://secwatch.observer/filing/0001232524-25-000025.json
- Plain text: https://secwatch.observer/filing/0001232524-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.